10,778
Views
2
CrossRef citations to date
0
Altmetric
Review Article

Pharmacotherapy of adjustment disorder: A review

ORCID Icon
Pages S46-S52 | Received 22 May 2018, Accepted 20 Jun 2018, Published online: 11 Sep 2018

References

  • Ansseau M, Bataille M, Briole G, De Nayer A, Fauchère PA, Ferrero F, Mertens C, Realini R, Rombaut P, Vereecken A, et al. 1996. Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression. Hum Psychopharmacol Clin Exp. 11:293–298.
  • Arbus C, Hergueta T, Duburcq A, Saleh A, Le Guern ME, Robert P, Camus V. 2014. Adjustment disorder with anxiety in old age: comparing prevalence and clinical management in primary care and mental health care. Eur Psychiatry. 29:233–238.
  • Arends I, Bruinvels DJ, Rebergen DS, Nieuwenhuijsen K, Madan I, Neumeyer-Gromen A, Bultmann U, Verbeek JH. 2012. Interventions to facilitate return to work in adults with adjustment disorders. Cochrane Database Syst Rev. 12:CD006389
  • Bachem R, Perkonigg A, Stein DJ, Maercker A. 2016. Measuring the ICD-11 adjustment disorder concept: validity and sensitivity to change of the Adjustment Disorder - New Module questionnaire in a clinical intervention study. International journal of methods in psychiatric research. 26:1545
  • Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, et al. 2014. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 28:403–439.
  • Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ. Care WTFoMDiP, Wfsbp Task Force on Anxiety Disorders OCD, Ptsd. 2012. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 16:77–84.
  • Bourin M, Bougerol T, Guitton B, Broutin E. 1997. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundam Clin Pharmacol. 11:127–132.
  • Carta MG, Balestrieri M, Murru A, Hardoy MC. 2009. Adjustment disorder: epidemiology, diagnosis and treatment. Clin Pract Epidemiol Ment Health. 5:15.
  • Casey P. 2014. Adjustment disorder: new developments. Curr Psychiatry Rep. 16:451.
  • De Leo D. 1989. Treatment of adjustment disorders: a comparative evaluation. Psychol Rep. 64:51–54.
  • De Wit S, Cremers L, Hirsch D, Zulian C, Clumeck N, Kormoss N. 1999. Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: a pilot study. J Int Med Res. 27:223–232.
  • Ferrer L, Kirchner T. 2015. Suicidal tendency among adolescents with adjustment disorder. Crisis 36:202–210.
  • Fielden JS. 2012. Review: management of adjustment disorder in the deployed setting. Mil Med. 177:1022–1027.
  • Galecki P, Zboralski K, Florkowski A. 2005. The efficacy and safety of trazodone in the treatment of adjustment disorders–naturalistic research. Pol Merkur Lekarski. 19:183–187.
  • Hameed U, Schwartz TL, Malhotra K, West RL, Bertone F. 2005. Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression. Ann Clin Psychiatry. 17:77–81.
  • Horowitz MJ. 1986. Stress-response syndromes: a review of posttraumatic and adjustment disorders. Hosp Community Psychiatry. 37:241–249.
  • Laugharne J, van der Watt G, Janca A. 2009. It is too early for adjusting the adjustment disorder category. Curr Opin Psychiatry. 22:50–54.
  • Maercker A, Brewin CR, Bryant RA, Cloitre M, van Ommeren M, Jones LM, Humayan A, Kagee A, Llosa AE, Rousseau C, et al. 2013. Diagnosis and classification of disorders specifically associated with stress: proposals for ICD-11. World Psychiatry. 12:198–206.
  • Miyasaka LS, Atallah AN, Soares BG. 2006. Valerian for anxiety disorders. Cochrane Database Syst Rev. 18:CD004515.
  • Miyasaka LS, Atallah AN, Soares BG. 2007. Passiflora for anxiety disorder. Cochrane Database Syst Rev. 24:CD004518.
  • Nesse RM, Stein DJ. 2012. Towards a genuinely medical model for psychiatric nosology. BMC Med. 10:5.
  • Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. 2006. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol. 21:139–149.
  • O’Keeffe N, Ranjith G. 2007. Depression, demoralisation or adjustment disorder? Understanding emotional distress in the severely medically ill. Clin Med (Lond). 7:478–481.
  • Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, Derde MP, Beauduin M, Piccart M. 1993. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. JCO. 11:1384–1390.
  • Razavi D, Kormoss N, Collard A, Farvacques C, Delvaux N. 1999. Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. J Int Med Res. 27:264–272.
  • Servant D, Graziani PL, Moyse D, Parquet PJ. 1998. Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study. L'Encephale 24:569–574.
  • Stahl SM. 2002. Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 63:756–757.
  • Stein DJ. 2015. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 32:57–68.
  • Stein DJ, Nesse RM. 2011. Threat detection, precautionary responses, and anxiety disorders. Neurosci Biobehav Rev. 35:1075–1079.
  • Strain JJ, Friedman MJ. 2011. Considering adjustment disorders as stress response syndromes for DSM-5. Depress Anxiety. 28:818–823.
  • Strain JJ, Smith GC, Hammer JS, McKenzie DP, Blumenfield M, Muskin P, Newstadt G, Wallack J, Wilner A, Schleifer SS. 1998. Adjustment disorder: a multisite study of its utilization and interventions in the consultation-liaison psychiatry setting. Gen Hosp Psychiatry. 20:139–149.
  • Syunyakov TS, Neznamov GG. 2016. [Evaluation of the therapeutic efficacy and safety of the selective anxiolytic afobazole in generalized anxiety disorder and adjustment disorders: results of a multicenter randomized comparative study of diazepam]. Ter Arkh. 88:73–86.
  • Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, et al. 2009. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ. 180:E47–E57.
  • Volz HP, Kieser M. 1997 . Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 30:1–5.
  • Woelk H, Arnoldt KH, Kieser M, Hoerr R. 2007. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 41:472–480.
  • Zeitler A, Kamoun N, Goyon S, Wahis J, Charlet A, Poisbeau P, Darbon P. 2016. Favouring inhibitory synaptic drive mediated by GABA(A) receptors in the basolateral nucleus of the amygdala efficiently reduces pain symptoms in neuropathic mice. Eur J Neurosci. 43:1082–1088.
  • Zimmerman M, Martinez JH, Dalrymple K, Chelminski I, Young D. 2013. “Subthreshold” depression: is. J Clin Psychiatry. 74:470–476.